Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference.

A webcast of the fireside chat will be available on the News & Events page, located within the Investors section of Checkpoint’s website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days after the meeting.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cSCC. Checkpoint is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib (formerly CK-101), a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.checkpointtx.com.

Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com

Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com  

Media Relations Contact:
Katie Kennedy
Gregory FCA
610-731-1045
Checkpoint@gregoryfca.com

Staff

Recent Posts

Britannia Announces Non-Brokered Private Placement of Unsecured Debenture Units

Britannia will undertake a non-brokered private placement of units consisting of subordinated dentures and common…

58 mins ago

Dr. Garrett Wirth Revolutionizes Breast Augmentation Recovery With Innovative 24-Hour Program

NEWPORT BEACH, CA / ACCESSWIRE / June 7, 2024 / Dr. Garrett Wirth, renowned plastic…

3 hours ago

Greene Concepts and Tocca Life Holdings Prominently Featured in National Broadcast Video

Marion, North Carolina--(Newsfile Corp. - June 7, 2024) - Greene Concepts Inc. (OTC Pink: INKW)…

4 hours ago

deCODE genetics: The rate, nature and transmission of mitochondrial DNA mutations in humans

A new study from deCODE genetics uses pedigrees and sequence data from 64,806 Icelanders to…

6 hours ago

Hospital PMI® at 58.4%; May 2024 Hospital ISM® Report On Business®

TEMPE, Ariz., June 7, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in May for…

6 hours ago